Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Botanix Pharmaceuticals Limited reports significant progress with their lead dermatology product Sofdra, anticipating FDA approval by late June 2024 and advancing negotiations with US insurers for coverage. The company is finalizing marketing strategies and has a healthy cash position of $17.32 million, poised to support operations through the expected approval date. The focus now shifts to commercial launch preparations, including telemedicine and sales team strategies for the treatment of primary axillary hyperhidrosis.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.
